PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26320862-3	2015	The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib.	ponatinib	89-98	receptor interacting serine/threonine kinase 2	Homo sapiens	16-21	
26320862-7	2015	We also determined the first crystal structure of RIPK2 bound to ponatinib, and identified an allosteric site for inhibitor development.	ponatinib	65-74	receptor interacting serine/threonine kinase 2	Homo sapiens	50-55	
29463017-3	2018	In this study, a pharmacophoric model based on the crystallographic pose of ponatinib, a potent RIPK2 inhibitor, and 30 other ones selected from the BindingDB repository database, was built.	ponatinib	76-85	receptor interacting serine/threonine kinase 2	Homo sapiens	96-101